Turns out the Dow doesnβt love it
22.02.2025 02:21 β π 6212 π 1158 π¬ 143 π 45@biolobri.bsky.social
Turns out the Dow doesnβt love it
22.02.2025 02:21 β π 6212 π 1158 π¬ 143 π 45www.project2025.observer
In case you want to keep trackβ¦
Pushback made a difference here.
In the face of loud "concerns from lawmakers and veterans advocates over the impact of the hiring freeze" the new admin scaled back its initial assault on the V.A....
cc @rieckhoff.bsky.social
www.militarytimes.com/veterans/202...
Let's iterate, not obliterate.
The US's research infrastructure is a thing of beauty.
Is its continued evolution necessary? Always! That's good policy and good science.
But, our primary focus should be expanding and strengthening the NIH, not stalling it. (4/4) π§ͺ
Sure, the NIH can be improved. I, too, have critiques on grant review.
But, its existing processes already offer substantial societal benefits while helping the US lead the #biotech sector.
That's good for science, our citizens, and US national security. (3/4) π§ͺ
www.csis.org/blogs/strate...
You'd be hard-pressed to find a better return for our taxes.
For every dollar of research funding, the NIH generates $2.46 in economic activity. π
Let's not understate that. Delaying NIH study sections, stalls a ~2.5X ROI & leaves value on the table. (2/4) π§ͺ
www.fiercebiotech.com/research/rep...
Continuing my concern train π, abruptly and indefinitely postponing #NIH study sections and advisory committees only delays important R&D activities.
Effective #BiomedicalResearch requires steady infrastructure and expert dialogue. The NIH provides that. (1/4) π§ͺ
www.statnews.com/2025/01/22/t...